BranchOut Food Welcomes Jesse Thomas as Chief Brand Officer to Drive Direct-to-Consumer and Brand Strategy
E-commerce Expansion and Brand Acceleration to Drive New Revenue Streams and Maximize Market Penetration
Key Focus Areas for Jesse Thomas:BEND, Ore., Feb. 19, 2025 (GLOBE NEWSWIRE) -- BranchOut Food Inc. (NASDAQ: BOF), a pioneer in the patented GentleDry™ dehydration technology, today announces the appointment of Jesse Thomas as its Chief Brand Officer. In this role, Thomas will lead the company's brand and marketing strategy, with a particular focus on expanding BranchOut's direct-to-consumer (DTC) business, complementing its rapidly growing branded retail, private label and industrial ingredient channels.
Thomas, best known as the Founder & CEO of Picky Bars, brings a proven track record of scaling DTC brands from concept to acquisition. Under his leadership, Picky Bars became a household name in the health and performance snack space, growing a 10,000+ subscriber base and establishing a multimillion-dollar e-commerce business that culminated in its $12M acquisition by Laird Superfood.
As BranchOut continues its rapid retail expansion in warehouse clubs, major grocery chains, and ingredient markets, Thomas will spearhead high-margin, recurring revenue streams in e-commerce, subscription models, and direct brand engagement.
Beyond his business acumen, Thomas is an accomplished professional athlete, having competed as an elite triathlete and Ironman champion. His deep connection to performance nutrition, active lifestyles, and consumer engagement has shaped his approach to brand building and DTC. This background makes him uniquely positioned to drive BranchOut's mission of delivering nutrient-dense, clean-label snacks that support active and health-conscious consumers.
Eric Healy, CEO of BranchOut Food, expressed enthusiasm about the new hire: "Jesse's proven track record in building and scaling DTC brands is exactly what we need as we expand our direct-to-consumer presence. His ability to connect with consumers, craft compelling brand narratives, and drive growth through digital channels will be instrumental in our next phase of expansion."
Thomas's leadership will enhance BranchOut's marketing strategy, helping to bring its cutting-edge GentleDry™ dehydrated snacks to a broader audience. As a pioneer in food innovation, BranchOut is leading the market with first-to-market, high-quality snack products made possible by its proprietary GentleDry™ technology. With a growing wholesale footprint and an exciting opportunity in DTC, the company is poised to redefine the shelf-stable snack category with superior taste, texture, and nutrition.
"I'm thrilled to join the BranchOut team and help take the brand to the next level," said Thomas. "BranchOut's breakthrough technology and commitment to creating best-in-class, high-quality snack products make this an exciting opportunity. I look forward to building a powerful direct-to-consumer channel that complements its already strong wholesale business."
With multi-million-dollar commitments already in place from top retailers, ingredient buyers, and private label partners, BranchOut is positioned for sustained, high-margin revenue growth across all channels. As mentioned in our January 15 press release, BranchOut remains on track to being cash flow positive starting this quarter and reaching $9 million in revenue in H1 2025.
About BranchOut Food Inc.
BranchOut Food is a leading international food technology company, specializing in the production of high-quality dehydrated fruit and vegetable-based products through its proprietary GentleDry Technology. This next-generation dehydration method preserves up to 95% of the original nutrition of fresh produce, offering superior quality and taste. Protected by over 17 patents, BranchOut's technology enables it to stand out as a trusted brand, ingredient and a private-label supplier. For more information, visit www.branchoutfood.com or follow us on social media here.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate", "plan," 'position', "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of BranchOut Food, Inc., (the Company) strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
Investor Relations Contact:
Jeff Ramson, CEO
PCG Advisory, Inc.
jramson@pcgadvisory.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
37 minutes ago
- Business Wire
Aera Technology Advances People-Centric Decision Intelligence with Agentic AI
LONDON--(BUSINESS WIRE)--Today at AeraHUB 25 London, the premier decision intelligence summit, Aera Technology will announce a major release of its industry-leading Aera Decision Cloud™, introducing a new wave of Agentic AI capabilities that empower users across roles and experience levels to harness AI to make smarter, faster decisions at scale. 'Aera Decision Cloud is the only platform that unifies the full decision-making context — blending structured and unstructured enterprise data, human expertise, and the reasoning capabilities of large language models." Fred Laluyaux, CEO, Aera Technology Share With this release, Aera Technology expands the frontier of people-centric decision intelligence. From the frontlines to the back office, any users can now tap the power of agents to build Aera Skills™ decision logic with natural language prompting — expanding decision-making use cases and unlocking value. A new AI-powered Data Wizard also allows data to be uploaded and categorized in seconds, and an enhanced Aera Chat interface delivers real-time insights, bringing the power of AI-driven decision-making directly into users' hands. 'Aera Decision Cloud is the only platform that unifies the full decision-making context — blending structured and unstructured enterprise data, human expertise, and the reasoning capabilities of large language models,' said Fred Laluyaux, Co-Founder, President, and CEO of Aera Technology. 'By putting these advanced capabilities directly in the hands of users, we're helping organizations achieve new levels of speed and agility in an increasingly complex world.' Meeting the Moment: AI for Today's Enterprise Challenges This comes at a pivotal time, when the speed and precision of decision execution can determine business success — and organizations face ongoing talent shortages, reskilling needs and increasing pressure to achieve tangible outcomes using AI technologies. Aera Technology's latest release redefines how decisions are made. By placing humans — regardless of technical expertise — at the center of creating AI-powered decision flows, Aera enables a shift from people doing data analysis to people architecting decision automation and overseeing action. This shift empowers business experts to increase their productivity and strategic impact. Key Innovations Rapid Skill Creation: Build Aera Skills™ with embedded AI agents that reason and act based on natural language instructions with built-in guardrails that ensure transparency, accountability, and governance. Any Data, Any Format: Tap into both structured and unstructured data sources — from transactional systems to PDFs and emails — to inform context-rich decisions. Enhanced Aera Cha t: Ask complex, data-driven questions in natural language and receive precise, actionable answers — with execution capabilities built directly into the chat. Smart Data Wizard: Upload data in seconds. The Data Wizard automatically classifies and prepares it for use — no technical training required. Key Benefits Data-Ready from Any Source: Seamlessly integrates structured and unstructured data — from systems, documents, and emails — to automate complex processes like claims management, procurement negotiations, and contract compliance. From Coding to Prompting: Accelerates time to value by defining decision intent in natural language. Agentic AI handles reasoning and generates decision logic. Autonomous, Scalable Collaboration: Communicates and coordinates across people, systems, and vendors, automating decision processes, such as negotiating order modifications. Fast Time to Action: Detects decision triggers, simulates alternatives, and executes actions autonomously. Join Us and See it in Action AeraHUB 25 London: The Decision Intelligence Summit June 11, 2025 | The Brewery, 52 Chiswell Street, London View the session lineup Learn more about Aera agentic decision intelligence Follow Aera Technology on LinkedIn for live updates and insights from the event. About Aera Technology Aera Technology, the decision intelligence company, created Aera, the first decision intelligence agent. Real-time and always-on, Aera understands how a business works, makes actionable recommendations, predicts business outcomes, executes decisions at scale, and learns from every decision. Supporting the full spectrum of decisions, from operational to strategic, Aera is powered by Aera Decision Cloud™ and its composable Aera Skills™. By empowering the world's leading companies to optimize decisions across the value chain, Aera is enabling a more sustainable, intelligent, and efficient world. Learn more at
Yahoo
2 hours ago
- Yahoo
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. This collaboration combines the MaxCyte ExPERT™ platform and proven Flow Electroporation® technology, widely recognized for its efficient and scalable transfection capabilities, utilized in over 19 active clinical and commercial programs, with Ori's innovative next-generation cell therapy manufacturing platform, IRO® (ee-RO). The collaboration will specifically evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T cells compared to traditional post-electroporation cell expansion processes. As a key component of this joint effort, Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation. MaxCyte's technology offers unparalleled flexibility and efficiency in transfecting cells at clinical scale, seamlessly integrating with diverse upstream and downstream processes within cell therapy workflows. The IRO platform complements this by introducing automated fluid handling, customizable mixing, and the OriConnect® tubeless sterile connection system, enhancing cell culture efficiency and scalability. Together, these complementary technologies provide therapy developers with a powerful toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently. Maher Masoud, President and CEO of MaxCyte, commented, 'We are excited to collaborate with the team at Ori Biotech, combining our respective strengths and innovative technologies to significantly enhance manufacturing processes. This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients.''Our partnership with MaxCyte is another example of Ori's dedication to providing flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing,' said Jason C. Foster, CEO of Ori Biotech. 'By integrating modular, best-of-breed technologies, we're raising the standard of manufacturing by enhancing commercial viability. Ultimately, this collaboration helps bring cell therapies to patients faster, more reliably, and at greater scale.' Through their shared commitment to innovation and industry collaboration, MaxCyte and Ori Biotech are enabling developers of advanced therapies to adopt integrated, best-of-breed solutions, accelerating the path from research to commercialization and making next-generation treatments more accessible to patients globally. About MaxCyte At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at and follow us on X and LinkedIn. About Ori Biotech Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori's next-generation manufacturing platform automates better biology, accelerates product development and enables therapy developers to scale their products' clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The promise of the innovative Ori platform is to automate cell therapy manufacturing, increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics. For news and updates, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits, outcomes, and impact of the collaboration between MaxCyte and Ori Biotech; the potential for improving clinical success and commercial viability through new manufacturing standards; and the intention to accelerate development timelines, increase access to next-generation cell therapies, and deliver transformative treatments to patients globally. These statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which MaxCyte operates, as well as management's current beliefs and assumptions. Words such as 'aims,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'should,' 'continue,' and variations of such words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict and are often beyond the control of the companies involved. Actual outcomes and results may differ materially from those expressed or implied in these forward-looking statements due to various factors, including changes in market conditions, technological advancements, regulatory developments, and the success of ongoing research and evaluation efforts. Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended May 8, 2025. These documents are available through the Investor Menu, Financials section, under 'SEC Filings' on the Investors page of our website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, MaxCyte does not undertake any obligation to update or revise any forward-looking statements to reflect new information, events, or circumstances after the date of this release. MaxCyte Contacts: US IR AdviserGilmartin GroupDavid Deuchler, CFA+1 415-937-5400ir@ Oak Street CommunicationsKristen Whitekristen@ Nominated Adviser and Joint Corporate BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500 UK IR AdviserICR HealthcareMary-Jane ElliottChris Welsh+44 (0)203 709 5700maxcyte@ Ori Biotech Contact: Debby Betzmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
2 hours ago
- Business Upturn
Biotalys Reports Progress in the Regulatory Review of EVOCA in both US and EU
By GlobeNewswire Published on June 11, 2025, 10:00 IST Ghent, BELGIUM, June 11, 2025 (GLOBE NEWSWIRE) — Press release Biotalys (Euronext – BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, is pleased to announce progress in the regulatory approval procedures in both the United States and Europe of its first protein-based biocontrol product, EVOCA™*. In the US, Biotalys received a communication from the Environmental Protection Agency (EPA) that the company has provided responses to all the agency's requests for additional information. The EPA currently projects it will complete the scientific review of the EVOCA dossier later this summer and make a regulatory decision by September 30th, 2025. In Europe, Biotalys is pleased to confirm that both the Dutch Board for Authorisation of Plant Protection Products (CTGB) and the Dutch Institute for Health and Environment (RIVM) have now provided positive evaluations of EVOCA's regulatory dossier, paving the way for the peer review phase at the European level. In their review, both Dutch authorities have classified EVOCA's active ingredient as low risk based on the current data. This classification is important as it recognizes the active ingredient's safety profile and aligns with Biotalys' commitment to delivering sustainable, effective solutions for crop protection. No critical areas of concern were identified and therefore the Netherlands, as rapporteur Member State, proposes that the active ingredient of EVOCA can be approved in Europe, subject to the provision of certain additional data during the peer review phase. Biotalys' current assessment is that a regulatory decision in the European Union can be expected in the second half of 2026. Kevin Helash, Chief Executive Officer of Biotalys, said: 'We are pleased with the regulatory progress in both the US and EU, and look forward to a favorable outcome. An approval decision would be a major milestone for our company and a validation for our unique AGROBODY™ technology platform. This platform has the potential to develop many more protein-based biocontrol solutions for growers to fight key pests and diseases in agriculture. I am very grateful for the thorough review and guidance by the regulatory agencies, and for the hard work by our team to generate and provide the required scientific data on our innovative product.' The first biocontrol developed on Biotalys' AGROBODY™ technology platform, EVOCA helps safely control fungal diseases Botrytis (grey mold) and powdery mildew for fruit and vegetable growers looking to add effective, biodegradable solutions to their integrated pest management (IPM) initiatives to reduce chemical applications. * EVOCA™: Pending Registration. This product is not currently registered for sale or use in the European Union, the United States or elsewhere and is not being offered for sale. About Biotalys Biotalys is an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for the protection of crops and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels since July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on For further information, please contact: Toon Musschoot, Head of IR & CommunicationT: +32 (0)9 274 54 00 E: [email protected] Important Notice Biotalys, its business, prospects and financial position remain exposed and subject to risks and uncertainties. A description of and reference to these risks and uncertainties can be found in the annual report on the consolidated annual accounts published on the company's website. This announcement contains statements which are 'forward-looking statements' or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'aim', 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. Biotalys' actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
